Trending With Impact: Multisite Cohort Study of Mutational Burden in Lung Cancer



February 2, 2022

Oncotarget published this trending research paper on January 31, 2022 in Volume 13, entitled, "Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study" by researchers from the Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT; Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, MN; Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Department of Hematology and Oncology, Baptist Health Medical Group, Lexington, KY; Department of Radiation Oncology, MetroHealth Medical Center, Cleveland, OH; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Department of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Precision Oncology Program, Saint Luke’s Cancer Institute, Kansas City, MO; Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY; US Medical Oncology, Bristol Myers Squibb, Princeton, NJ; Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ; Global Medical Oncology, Bristol Myers Squibb, Princeton, NJ. DOI - Correspondence to - Connor Willis - Abstract: Background: Tumor mutational burden (TMB) is a potential biomarker to predict tumor response to immuno-oncology agents in patients with metastatic non-small cell lung cancer (NSCLC). Materials and Methods: A multi-site cohort study evaluated patients diagnosed with stage IV NSCLC between 2012 and 2019 who had received comprehensive genomic profiling (CGP) and any NSCLC-related treatment at 9 U.S. cancer centers. Baseline characteristics and clinical outcomes were compared between patients with TMB 10 showed a significant association towards longer overall survival (OS) (HR: 0.43, 95% CI: 0.21–0.88, p = 0.02) and progression-free survival (PFS) (HR: 0.43, 95% CI: 0.21–0.85, p = 0.02) in patients treated with first-line immunotherapy and tested by Foundation Medicine or Caris at treatment initiation. Conclusions: TMB levels greater than or equal to 10 mut/Mb, when tested by Foundation Medicine or Caris at treatment initiation, were significantly associated with improved OS and PFS among patients treated with first-line immunotherapy-containing regimens. Additional prospective research is warranted to validate this biomarker along with PD-L1 expression. Sign up for free Altmetric alerts about this article - Keywords - lung neoplasma, tumor biomarkers, immunotherapy About Oncotarget Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit and connect with us: SoundCloud - Facebook - Twitter - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Oncotarget is published by Impact Journals, LLC: Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Analytical TechniquesCancer ResearchImmunologyMolecular Biology

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.